Drug Profile
ADN MCL
Alternative Names: ADN-MCLLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator ADIENNE
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mantle-cell lymphoma
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Mantle-cell-lymphoma in Switzerland
- 02 Aug 2017 Preclinical trials in Mantle cell lymphoma in Switzerland before August 2017 (ADIENNE pipeline, August 2017)